Cargando…
Human and mouse albumin bind their respective neonatal Fc receptors differently
Albumin has a serum half-life of three weeks in humans and is utilized to extend the serum persistence of drugs that are genetically fused or conjugated directly to albumin or albumin-binding molecules. Responsible for the long half-life is FcRn that protects albumin from intracellular degradation....
Autores principales: | Nilsen, Jeannette, Bern, Malin, Sand, Kine Marita Knudsen, Grevys, Algirdas, Dalhus, Bjørn, Sandlie, Inger, Andersen, Jan Terje |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6168492/ https://www.ncbi.nlm.nih.gov/pubmed/30279529 http://dx.doi.org/10.1038/s41598-018-32817-0 |
Ejemplares similares
-
Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics
por: Sand, Kine Marita Knudsen, et al.
Publicado: (2015) -
An intact C-terminal end of albumin is required for its long half-life in humans
por: Nilsen, Jeannette, et al.
Publicado: (2020) -
A human endothelial cell-based recycling assay for screening of FcRn targeted molecules
por: Grevys, Algirdas, et al.
Publicado: (2018) -
The Neonatal Fc Receptor (FcRn): A Misnomer?
por: Pyzik, Michal, et al.
Publicado: (2019) -
Structure-based mutagenesis reveals the albumin-binding site of the neonatal Fc receptor
por: Andersen, Jan Terje, et al.
Publicado: (2012)